LDL receptor related protein 11Genealiases: MANSC3 · bA350J20.3
Q-omics provides the consensus-scored LRP11 profile across patient tissues and cancer cell-line models. LRP11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LRP11 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, LRP11 RNA expression shows 19,471 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where LRP11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRP11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRP11 survival associations across molecular data types. LRP11 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRP11 RNA expression–survival associations across cancer types. High LRP11 expression shows unfavorable associations in HNSC, LIHC, KIRP, ACC and LUAD, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LRP11 RNA expression.
This table summarizes LRP11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRP11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRP11 shows higher tumor expression in COAD, HNSC, BLCA, LIHC, LUAD and BRCA. The COAD box plot shows higher LRP11 RNA expression in tumor versus normal tissue (log2 FC = +1.148, t-test p < 0.001).
This table shows molecular features associated with LRP11 in patient tissues and cancer cell lines. In patient samples, LRP11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRP11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
